FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
FibroBiologics, Inc. (Nasdaq: FBLG), a biotech firm holding over 270 patents, disclosed promising preclinical findings. The results indicate that utilizing human dermal fibroblast (HDF) spheroids topically can alter the burn wound environment positively. This treatment approach demonstrated the ability to decrease damaging inflammation, modify immune cell response, and lessen indicators of scar formation within eight days post-injury.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments